What's Happening?
RareCyte, a leader in precision biology, has announced the expansion of its spatial proteomics portfolio with the launch of Orion HT and Orion LE systems. These systems are designed to enhance biomarker development and clinical research. The company also
appointed Neil Kennedy as President to lead its commercial strategy. The Orion platform aims to deliver high-throughput, high-plex spatial proteomics, facilitating applications such as patient stratification and therapy response assessment. RareCyte's expansion includes a growing reagent portfolio, expected to reach over 300 antibodies by the end of 2026.
Why It's Important?
The expansion of RareCyte's spatial proteomics capabilities represents a significant advancement in clinical and translational research. By providing high-throughput and high-plex solutions, the Orion systems enable more precise biomarker development, which is crucial for personalized medicine and targeted therapies. This development could accelerate the adoption of spatial biology in clinical settings, improving patient outcomes and advancing drug development. The appointment of Neil Kennedy as President further strengthens RareCyte's leadership, positioning the company for global growth in the life sciences sector.
